An ultrasensitive assay for diagnosis of Alzheimer's disease.
Alzheimer's disease (AD) is a chronic neurodegenerative disorder and the most common cause of dementia. Aging is among the most significant risk factors. Today, AD can be diagnosed with certainty only post mortem, detecting insoluble beta-amyloid peptide (Abeta) aggregates in the patient's brain tissue. We have developed an ultrasensitive assay for early and non-invasive diagnosis of AD. This highly specific and sensitive assay uses fluorescence correlation spectroscopy (FCS) and is sensitive enough to detect even single aggregates in body fluids of AD patients. We investigate the correlation of aggregated Abeta concentrations in body fluids with clinical symptoms of AD.
Funke
Susanne Aileen
SA
Forschungszentrum Jülich, INB-2, Jülich, Germany.
Birkmann
Eva
E
Henke
Franziska
F
Görtz
Philipp
P
Lange-Asschenfeldt
Christian
C
Riesner
Detlev
D
Willbold
Dieter
D
D000544:Alzheimer Disease / Q000175:diagnosis*; D016229:Amyloid beta-Peptides / Q000134:cerebrospinal fluid / Q000138:chemical synthesis / Q000737:chemistry; D006801:Humans; D020836:Protein Structure, Quaternary; D012680:Sensitivity and Specificity; D013050:Spectrometry, Fluorescence / Q000379:methods*
D016229:Amyloid beta-Peptides